An Overview of ALK+ NSCLC

You’ve been diagnosed with ALK+ NSCLC, which means you’ve probably got a lot of questions. Let’s start by answering the basics.

What is NSCLC?

Non-small cell lung cancer, or NSCLC, is the most common type of lung cancer. It makes up about 85% of lung cancer cases.

In some cases of NSCLC, a genetic change, or mutation, in the cell’s genes causes the cell to function improperly and grow more quickly, which may lead to cancer.

What Does ALK-Positive Mean?

In some people, lung cancer is caused by a change in the structure of the gene called anaplastic lymphoma kinase (ALK). About 3% to 5% of people with NSCLC have this change in the ALK gene. This type of lung cancer is most frequently seen in non-smokers or light smokers and younger patients.

How Can Targeted Therapies Help?

Although there is no cure, ALK+ (anaplastic lymphoma kinase-positive) NSCLC can be treated with targeted therapies that affect this specific gene found in cancer cells to help block the growth or spread of cancer.


What if ALK+ NSCLC Has Spread Beyond Your Lungs?

ALK+ NSCLC Metastasis

ALK-positive NSCLC is a disease that often progresses beyond the lungs. Progression is when tumors grow, spread to other parts of the body (called metastasis), or when new tumors develop while on treatment. When cancer progresses, it can spread to many locations, including the liver, bone, and the brain.

Illustration of patient highlighting all of the locations where cancer can spread, including the liver, lungs, bone, and brain

With ALK+ NSCLC, Your Brain Matters Too

Because current treatments are more effective and people with ALK-positive NSCLC go longer without disease progression, up to 75% of patients may eventually experience the disease traveling to their brains.

An effective treatment that targets multiple areas of metastasis, including the lungs and brain, may delay disease progression.


How ALUNBRIG Works

Glossary

ALK gene-A gene that makes a protein called anaplastic lymphoma kinase or ALK, which is involved in cell growth. Mutated or genetically changed forms of the ALK gene and protein have been found in some types of cancer, such as NSCLC.

Metastasis-The spread of cancer from the original site to another part of the body.

Targeted therapies-A type of treatment that can inhibit or slow the disease growth, progression, and spread of cancer by targeting specific molecules that are responsible for cancer cell growth. Some targeted therapies block the action of certain enzymes, proteins, or other molecules involved in the growth and spread of cancer cells.

A gene that makes a protein called anaplastic lymphoma kinase or ALK, which is involved in cell growth. Mutated or genetically changed forms of the ALK gene and protein have been found in some types of cancer, such as NSCLC.

The spread of cancer from the original site to another part of the body.

A type of treatment that can inhibit or slow the disease growth, progression, and spread of cancer by targeting specific molecules that are responsible for cancer cell growth. Some targeted therapies block the action of certain enzymes, proteins, or other molecules involved in the growth and spread of cancer cells.


ALUNBRIG(TM) BRIGATINIB 39 mg TABLETS

This site is intended for residents of the US and US territories only.

ALUNBRIG(TM) BRIGATINIB 39 mg TABLETS

This site is intended for residents of the US and US territories only.

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib) and entering one that is not owned or controlled by Takeda Oncology.

Takeda Oncology makes no representation as to the accuracy of the information contained on sites we do not own or control. Takeda Oncology does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Cancel Continue +

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib) and entering one that is not owned or controlled by Takeda Oncology.

This link will take you to the corporate ARIAD Pharmaceuticals, Inc. website.

Cancel Continue
Close

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib).

This link will take you to another Takeda Oncology website.

Cancel Continue +

The site you are about to enter is intended for US healthcare professionals only.

Please confirm that you are a US healthcare professional.

Yes, I confirm that I am a US healthcare professional Cancel +

In Vitro: ALUNBRIG Inhibited 17
ALK-Inhibitor-Resistant Mutations1,2

ALUNBRIG exhibited in vivo antitumor activity against 4 mutant forms of EML4-ALK, including the G1202R and L1196M mutants identified in NSCLC tumors in patients who had progressed on crizotinib.


 
 
 

We use cookies to gather web statistics that help us improve our site. We store no personal details.
ACCEPT

Read More